Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAY-339604
- Development stage
- Discontinued
- Lead developer
- Bayer
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
BAY-339604 is an antisense oligonucleotide (ASO) developed by Ionis Pharmaceuticals in collaboration with Bayer as a follow-on candidate to fesomersen (IONIS-FXI-LRx) for the treatment of thrombotic diseases. It is designed to target the mRNA of Coagulation Factor XI (FXI), thereby inhibiting the hepatic production of the FXI protein and providing an antithrombotic effect with a potentially improved safety profile. In late 2019, Bayer exercised its option to advance this follow-on compound, triggering a $10 million milestone payment to Ionis. BAY-339604 entered Phase 1 clinical development in 2020 (NCT04534114) to evaluate its safety, pharmacokinetics, and pharmacodynamics in healthy subjects. However, in 2022, Bayer decided to discontinue its collaboration with Ionis on the Factor XI antisense program, leading to the cessation of development for BAY-339604.
- Other names
- Factor XI antisense follow-on
02
Targets
F11 (Coagulation Factor XI)
Beyond the preview
Go deeper on BAY-339604.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAY-339604.